LG AI Research and D&D Pharmatech Team Up to Accelerate AI-Driven Oral Peptide Drug Discovery

Developing peptide-based medicines has historically been a slow and expensive process, hampered in part by a fundamental biological challenge: peptides are fragile molecules that the digestive system tends to break down before they can reach their target. Now, a newly announced partnership between LG AI Research and South Korean biotech firm D&D Pharmatech is betting that artificial intelligence can help crack that problem faster than conventional drug-discovery methods alone.

What the Collaboration Involves

Under a master agreement reported in mid-2025, LG AI Research will contribute its large-scale AI modelling capabilities to D&D Pharmatech's pipeline of oral peptide drug candidates. The goal, according to announcements from both organisations, is to use AI-driven design and screening tools to identify peptide sequences that are not only biologically active but also stable enough to survive the gastrointestinal environment and be absorbed into the bloodstream when taken by mouth.

Oral bioavailability is widely considered one of the most stubborn obstacles in the peptide therapeutics field. A detailed analysis published in Science described the engineering hurdles involved in building an orally delivered peptide drug, noting that researchers must simultaneously optimise molecular stability, permeability, and potency — properties that can work against one another. AI models trained on large chemical and biological datasets are increasingly being explored as a way to navigate that complex design space more efficiently.

Where AI Fits Into Peptide Research

Machine learning approaches can, in principle, scan vast libraries of potential peptide sequences and predict which candidates are most likely to meet multiple criteria at once — a task that would take research teams years to work through experimentally. LG AI Research has previously developed large language and multimodal models; applying similar architectures to molecular biology represents a growing trend across the pharmaceutical industry.

D&D Pharmatech, for its part, has focused specifically on oral peptide formulation technology, giving the collaboration a pairing of computational power with experimental platform expertise. Researchers in the field have noted that combining AI-based candidate generation with robust in vitro and in vivo testing pipelines could meaningfully compress early discovery timelines, though translating computational predictions into clinical-stage drugs remains a lengthy and uncertain process.

Broader Context: Peptides Under the Spotlight

The announcement arrives at a moment of heightened public and scientific interest in peptides. Coverage from outlets including NPR and university newsrooms has noted that peptides are attracting attention well beyond specialist research circles, prompting calls for clearer communication about what the science actually supports at this stage. Meanwhile, separate preclinical work — such as recently reported studies on brain-protective peptides in Parkinson's disease models — illustrates how diverse the potential application space has become.

Industry observers caution that even with AI acceleration, most peptide programmes that look promising in early computational or laboratory stages do not ultimately succeed in human clinical trials. The LG AI Research and D&D Pharmatech collaboration is at an early stage, and no clinical candidates from this specific agreement have yet been publicly disclosed.

Key Takeaways

• Partnership scope: LG AI Research brings large-scale AI modelling; D&D Pharmatech contributes oral peptide platform technology.
• Core challenge being addressed: Improving the oral bioavailability and stability of therapeutic peptides.
• Current stage: Early-phase collaboration; no clinical candidates have been announced yet.
• Industry trend: AI-assisted drug discovery is increasingly being applied to the peptide therapeutics sector across multiple companies.

This article is general educational information about peptide research and is not medical advice.